Design and development of a sweat-based glucose monitoring graphene nanodevice (closed-loop) with controlled transdermal nanoemulsion release for hypoglycemic drug delivery
The present project aims to design and develop an innovative wearable device for the prevention, diagnosis and treatment of diabetes mellitus which will make use of novice graphene structures.
The implementation of this task will rely on three individual actions and more specifically:
Smart Expertise Product
The final product (Actions A, B and C) will be a product of a smart expertise in the area of biomedicine and pharmacy which deploy the tremendous development of biotechnology, computer science and material engineering the last decade. The implementation of this project is expected to contribute not only scientifically and economically to the participating departments as well as the company and the country, but mainly will contribute to the management of diabetes mellitus and the improvement of the quality of life of the diabetic patients.
The suggested effort of research is fully in line with the Research and Innovation Strategy for Smart Specialization (RIS3) which aims to the development of new products for the prevention, diagnosis and treatment of diseases.
The project proposes the design and development of an innovative diagnostic and therapeutic device that will make use of novel graphene structures. The implementation of the project will be based on three sub-actions and specifically:
- The development of a sensitive bio-glucose sensor in sweat based on graphene. Graphene sheets with state-of-the-art Langmuir Blogget technology will be deposited to immobilize compounds that have the ability to bind glucose. The biosensor will be an adhesive patch that will continuously measure sweat glucose levels and will therefore be a non-invasive diagnostic method.
- The development of a system of prolonged release of hypoglycemic therapy. SGLT-2 inhibitors and GLP-1 analogues, active compounds used in the treatment of type 2 diabetes, will be trapped in nanoemulsions. The nanoemulsions will have lipophilic properties and will be placed in gelatin patches which will adhere to the surface of the skin like the bio-sensor.
- The development of a device / software which, through Bluetooth technology, will receive electrical signals from the bio-sensor, will analyze the change of glucose levels in sweat and will signal the release of the nanoemulsion of the patch by heating. The final product (Actions A, B and C) will be an object of smart specialization in the field of biomedicine and pharmacy which utilizes the strong development that has shown in the last decade materials science, biotechnology and information technology.
The implementation of the program is expected to offer not only scientific and financial benefits to the participating institutions and the company as well as in our country, but mainly in the management of diabetes and in improving the quality of life of a large number of people as it aims to develop a closed control system (closed-loop) and finally the fully automated control of diabetes mellitus with continuous measurements of glucose levels and administration of hypoglycemic substance.
The proposed research activity is fully aligned with the revised priorities of the National Intelligent Strategy Strategy (RIS3) which aims to develop diagnostic and therapeutic devices for controlled drug delivery for more effective and targeted individualized treatment.
Department of Materials Science and Engineering – Laboratory of Layered and Nanoporous Materials
- Dimitrios Gournis, Professor of Materials Chemistry
- Michael Karakassides, Professor
- DemetriosPapayannis, AssociateProfessor
- Vasilios Georgakilas, Associate Professor, University of Patras
- AthanasiosBourlinos, Associate Professor
- Konstantinos Spyrou, Postdoctoral researcher
- Mohammed Subrati, Postdoctoral researcher
- Victoria Sakavitsi, Phd candidate
School of Health Sciences
Medical Department – Laboratory of Physiology
- Dimitrios Peschos, Professor of Physiology
- Patra Vezyraki, Professor of Physiology
- Periklis Pappas, Professor of Pharmacology
- Konstantinos Tsamis, Assistant Professor of Physiology
- Yannis Simos, Senior Research Associate
- Efterpi Korakaki, Phd candidate
- Panagiotis Lekkas, Laboratory Animal Technician
- Christos Cholevas, Postdoctoral researcher
Department of Biological Applications – Laboratory of Biotechnology
- Haralambos Stamatis, Professor of Biotechnology
- Angeliki Polydera, Laboratory Teaching Staff
- Michaela Patila, Postdoctoral researcher
- Georgios Bakratsas, Phd candidate
- Evangelia Dounousi, Assistant Professor of Nephrology
- Konstnatinos Kostikas, Associate Professor of Pneumonology
- Eirini Papanikolaou, Phd candidate
- Silvia Priska, Biologist-Biotechnologist
The current project is a joint collaboration of the Laboratory of Physiology (Faculty of Medicine), the Laboratory of Biotechnology (Department of Biological Applications and Technologies), the Ceramics and Composites laboratory (Department of Materials Science and Engineering) of the University of Ioannina, the Renal Unit of the University Hospital of Ioannina, the Department of Electrical and Computer Engineering of the University of Western Macedonia and the private R&D and Business Development Organization Pharma-Data S.A.
Demigod Research Project
 Bamgboje, David et al. “Continuous Non-Invasive Glucose Monitoring via Contact Lenses: Current Approaches and Future Perspectives.” Biosensors vol. 11,6 189. 9 Jun. 2021, doi:10.3390/bios11060189
 V. Fiska, S. Evangelou, N. Giannakeas, M. G. Tsipouras, “DEMIGOD: System Architecture of a Sweat-Based Glucose Monitoring Closed-Loop System with Controlled Transdermal Nanoemulsion Release for Hypoglycemic Treatment”, 9th Panhellenic Conference on Biomedical Technologies, 9-11 September 2021, Thessaloniki, Greece (Virtual Conference)
3) Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, Ilias P. Nikas, Chryssa Bekiari, Stavroula A. Paschou, Dimitrios Peschos, Spyridon Konitsiotis, Patra Vezyraki & Konstantinos I. Tsamis (2022) New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs, Expert Opinion on Investigational Drugs, 31:1, 105-123, DOI: 10.1080/13543784.2022.2022122